Justin Klee (L) and Josh Cohen (Amylyx)
October 5, 2022 06:49 AM EDTUpdated 08:29 AM
Financing

Amy­lyx snatched the land­mark ap­proval for its ALS drug. Now it’s seek­ing cash to foot the launch bill

Amber Tong

As Amy­lyx gets ready to de­but its ALS drug in the US — amid scruti­ny and crit­i­cism of the price it’s set — the biotech is go­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

A service from the Financial Times